Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials

Abstract

The systematic treatment based on gemcitabine plus cisplatin is recommended as the current standard chemotherapy for unresectable or metastatic biliary tract cancers. However, the exact benefits from the recognized regime are still dismal. We thus elicit this study in an attempt to analyze whether targeted therapy coupled with various chemotherapy could produce improvement of survival benefits. The clinical trials were searched electronically from databases till July 2016 published in English and Chinese. Nine hundred and sixty-four patients from 7 trials were identified in our analysis. The overall analysis achieved a significantly higher overall response rate (ORR) among the patients treated with targeted drugs plus chemotherapy than chemotherapy alone (OR=1.87; 95% CI: 1.37–2.57; P=0.000), but failed in the overall progression-free survival (PFS) [mean difference (MD)=0.63; 95% CI:–0.45–1.72; P=0.26] and overall survival (OS) (MD=–0.67; 95% CI:–2.54–1.20; P=0.49). In the sub analysis, better ORR was obtained with the addition of EGFR (OR=1.75; 95% CI: 1.20–2.56; P=0.004) and VEGFR (OR=2.5; 95% CI: 1.28–4.87; P=0.007) targeted therapy. Furthermore, the sub analysis of EGFR target showed an significant improvement on PFS (MD=1.36; 95% CI: 0.29–2.43; P=0.01). No significant differences were observed in the incidences of neutropenia (OR=1.37; 95% CI: 0.89–2.12), thrombocytopenia (OR=1.40; 95% CI: 0.83–2.39), anemia (OR=1.21; 95% CI: 0.62–2.38), peripheral neuropathy (OR=1.52; 95% CI: 0.81–2.88), increased AST/ALT (OR=1.40; 95% CI: 0.82–2.39) as well as fatigue (OR=1.65; 95% CI: 0.96–2.84) in either of the treatment groups. In conclusion, better ORR associated with chemotherapy combined with targeted therapy (both targeting EGFR and VEGF) is found in the present meta-analysis without the cost of increased unacceptable toxicities, but regretfully not for the OS. The sub-analysis of targeting EGFR instead of VEGF obtains a superior PFS. Otherwise, there is no statistically significant difference in the overall PFS between the combination regime and chemotherapy alone. Given the paucity of favorable data, we need further studies to characterize optimal targeted agents to confirm the potential value to biliary tract cancer.

Keywords

biliary tract cancer / gallbladder cancer / cholangiocarcinoma / targeted therapy / chemotherapy

References

[1] GeynismanDM, CatenacciDV. Toward personalized treatment of advanced biliary tract cancers. Discov Med, 2012, 14(74): 41-57 PMID: 22846202

[2] HezelAF, ZhuAX. Systemic therapy for biliary tract cancers. Oncologist, 2008, 13(4): 415-423 PMID: 18448556

[3] ValleJ, WasanH, PalmerDH, et al. . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. Expert Rev Gastroenterol Hepatol, 2014, 4(4): 395-397

[4] ValleJW, WasanH, JohnsonP, et al. . Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase ? study-The UK ABC-01 Study. Br J Cancer, 2009, 101(4): 621-627 PMID: 19672264 PMCID: 2736816

[5] OkusakaT, NakachiK, FukutomiA, et al. . Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer, 2010, 103(4): 469-474 PMID: 20628385 PMCID: 2939781

[6] InGH, HongSS, MyungAL, et al. . Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis. Cancer Chemother Pharmacol, 2014, 74(6): 1291-1296

[7] AmartejM, KennethGL, LakshmiR. Targeted therapy in biliary tract cancers. Curr Treat Options Oncol, 2015, 16(10): 48-65

[8] LeeJ, ParkSH, ChangHM, et al. . Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2012, 13(2): 181-188 PMID: 22192731

[9] MalkaD, CerveraP, FoulonS, et al. . Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol, 2014, 15(8): 819-828 PMID: 24852116

[10] ChenJS, HsuC, ChiangNJ, et al. . A KRAS mutation status-stratified randomized phase ? trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol, 2015, 26(5): 943-949 PMID: 25632066

[11] LeoneF, MarinoD, CeredaS, et al. . Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). Cancer, 2016, 122(4): 574-581 PMID: 26540314

[12] ValleJW, WasanH, LopesA, et al. . Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol, 2015, 16(8): 967-978 PMID: 26179201 PMCID: 4648082

[13] MoehlerM, MadererA, SchimanskiC, et al. . Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase ? AIO study with biomarker and serum programme. Eur J Cancer, 2014, 50(18): 3125-3135 PMID: 25446376

[14] SantoroA, GebbiaV, PressianiT, et al. . A randomized, multicenter, phase ? study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Ann Oncol, 2015, 26(3): 542-547 PMID: 25538178

[15] JordanE, Abou-AlfaGK, LoweryMA. Systemic therapy for biliary cancers. Chin Clin Oncol, 2016, 5(5): 65-78 PMID: 27829278

[16] EricIM, NelsonSY. Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol, 2016, 22(4): 1335-1347

[17] KimST, JangKT, LeeSJ, et al. . Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase ? study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer, 2015, 15(1): 530-537 PMID: 26189560 PMCID: 4507321

[18] EckelF, SchmidRM. Chemotherapy and targeted therapy in advanced biliary tract carcinoma a pooled analysis of clinical trials. Chemotherapy, 2014, 60(1): 13-23 PMID: 25341559

[19] LeeJK, CapanuM, O’ReillyEM, et al. . A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br J Cancer, 2013, 109(4): 915-919 PMID: 23900219 PMCID: 3749586

[20] BengalaC, BertoliniF, MalavasiN, et al. . Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer, 2010, 102(1): 68-72 PMID: 19935794

[21] PengH, ZhangQ, LiJ, et al. . Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget, 2016, 7(13): 17220-17229 PMID: 26967384 PMCID: 4941382

[22] DohertyMK, KnoxJJ. Adjuvant therapy for resected biliary tract cancer: a review. Chin Clin Oncol, 2016, 5(5): 64-76 PMID: 27701873